MedTrace Logo

Clinical Trial to Assess the Efficacy and Safety of YYD601 in NERD Patients

NCT03967886 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 170

Last updated 2021-05-11

No results posted yet for this study

Summary

Clinical Trial to Assess the Efficacy and Safety of YYD601 in NERD Patients

Conditions

  • Non-erosive Reflux Disease

Interventions

DRUG

YYD601 20mg

Patients should take drugs an hour before breakfast.

DRUG

Nexium 20mg

Patients should take drugs an hour before breakfast.

DRUG

Placebos

The placebo YYD601 is made from microcrystalline cellulose covered with hard shell. The placebo Nexium is made from microcrystalline cellulose, Crospovidone, Magnesiumstearat and other ingredients.

Sponsors & Collaborators

  • Yooyoung Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-10
Primary Completion
2019-12-20
Completion
2020-05-27

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03967886 on ClinicalTrials.gov